ClinicalTrials.gg
Active, not recruitingNCT03785249Updated Jul 29, 2026

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

A Phase 1/2 interventional study of MRTX849 and Pembrolizumab in Advanced Cancer, Metastatic Cancer and Malignant Neoplastic Disease, sponsored by Mirati Therapeutics Inc.. Active, not recruiting at 222 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
731
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
3rd of 44
731 · median 66
Started
2019
with 3 others
Phase 1/2
9 of 50
1 open now
Registered
31st of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2019, is one of 9 in phase 1/2, and was the 31st registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Read the detailed description

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer
  • Malignant Neoplastic Disease

Keywords

  • KRAS
  • NSCLC
  • Colorectal Cancer
  • Colon Cancer
  • Metastatic Cancer
  • Pancreatic Cancer
  • Adagrasib
  • STK11 mutation
  • KRAS G12C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a solid tumor with KRAS G12C mutation
  • Unresectable or disease
  • Standard treatment is not available or patient declines; treatment for NSCLC for certain cohorts
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • History of intestinal disease or major gastric surgery or inability to swallow oral medications
  • Other active cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
731 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Exploration

    Dose escalation of MRTX849 to determine maximum tolerated dose

    Drug: MRTX849

  • Experimental
    Phase 1b Expansion

    Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens

    Drug: MRTX849

  • Experimental
    Phase 2

    Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849

    Drug: MRTX849

  • Experimental
    Pilot Phase 1b Combination with Pembrolizumab

    Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC

    Drug: MRTX849 · Drug: Pembrolizumab

  • Experimental
    Pilot Phase 1b Combination with Cetuximab

    Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC

    Drug: MRTX849 · Drug: Cetuximab

  • Experimental
    Pilot Phase 1b Combination with Afatinib

    Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC

    Drug: MRTX849 · Drug: Afatinib

  • Experimental
    Phase 2 Combination with Cetuximab

    Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC

    Drug: MRTX849 · Drug: Cetuximab

  • Experimental
    Pilot Phase 1b Combination with Cetuximab in NSCLC

    Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC

    Drug: MRTX849 · Drug: Cetuximab

  • Experimental
    Pilot Phase 1b Combination with Cetuximab in PDAC

    Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)

    Drug: MRTX849 · Drug: Cetuximab

Interventions

  • MRTX849 will be administered orally once or twice daily in a continuous regimen

  • Pembrolizumab is administered as an intravenous infusion once every 3 weeks

  • Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks

  • Afatinib will be administered orally once a day in a continuous regimen

06

What researchers measure

Primary outcomes

  1. Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation

    Number of participants with treatment related adverse events

    Time frame: 20 months

  2. Evaluate the pharmacokinetics of MRTX849

    Blood plasma concentration

    Time frame: 20 months

  3. Evaluate clinical activity/efficacy of MRTX849

    Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: 20 months

Secondary outcomes

  1. Establish maximum tolerated dose

    Number of participants with dose limiting toxicity

    Time frame: 12 months

  2. Characterize safety and tolerability of MRTX849 in combination with selected therapeutic agents

    Number of participants with dose limiting toxicity

    Time frame: 12 months

  3. Evaluate the pharmacokinetics of new MRTX849 oral formulations

    Blood plasma concentration

    Time frame: 6 months

  4. Evaluate the pharmacokinetics of MRTX849 administered with food

    Blood plasma concentration

    Time frame: 6 months

07

Study locations

222 sites
  • Local Institution - 001-826
    Birmingham, Alabama 35294, United States
  • Local Institution - 001-965
    Anchorage, Alaska 99508, United States
  • Local Institution - 001-821
    Phoenix, Arizona 85054, United States
  • Local Institution - 001-873-A
    Tucson, Arizona 85704, United States
  • Local Institution - 001-873
    Tucson, Arizona 85704, United States
  • Local Institution - 001-840-B
    Bellflower, California 90706, United States
  • Local Institution - 001-834
    Beverly Hills, California 90211, United States
  • Local Institution - 001-843
    Duarte, California 91010, United States
  • Local Institution - 001-850-K
    Dublin, California 94568, United States
  • Local Institution - 001-851
    Fullerton, California 92835, United States
  • Local Institution - 001-840-C
    Harbor City, California 90710, United States
  • Local Institution - 001-805
    La Jolla, California 92093, United States
  • Local Institution - 001-779
    Los Alamitos, California 90720, United States
  • Local Institution - 001-840
    Los Angeles, California 90027, United States
  • Local Institution - 001-578
    Los Angeles, California 90067, United States
  • Local Institution - 001-847
    Newport Beach, California 92663, United States
  • Local Institution - 001-850-B
    Oakland, California 94611, United States
  • Local Institution - 001-803
    Orange, California 92868, United States
  • Local Institution - 001-850-C
    Roseville, California 95661, United States
  • Local Institution - 001-850-J
    Sacramento, California 95814, United States
  • Local Institution - 001-850-D
    Sacramento, California 95825, United States
  • Local Institution - 001-845
    San Diego, California 92111, United States
  • Local Institution - 001-840-A
    San Diego, California 92120, United States
  • Local Institution - 001-850-H
    San Francisco, California 94080, United States
  • Local Institution - 001-850-E
    San Francisco, California 94115, United States
  • Local Institution - 001-850-F
    San Jose, California 95119, United States
  • Local Institution - 001-850-A
    San Leandro, California 94577, United States
  • Local Institution - 001-884
    Santa Barbara, California 93105, United States
  • Local Institution - 001-850-I
    Santa Clara, California 95051, United States
  • Local Institution - 001-884-A
    Solvang, California 93463, United States
  • Local Institution - 001-850
    Vallejo, California 94589, United States
  • Local Institution - 001-850-G
    Walnut Creek, California 94596, United States
  • Local Institution - 001-872
    Aurora, Colorado 80012, United States
  • Local Institution - 001-810
    Aurora, Colorado 80045, United States
  • Local Institution - 001-872-H
    Boulder, Colorado 80303, United States
  • Local Institution - 001-872-E
    Colorado Springs, Colorado 80907, United States
  • Local Institution - 001-872-L
    Colorado Springs, Colorado 80920, United States
  • Local Institution - 001-872-B
    Denver, Colorado 80218, United States
  • Local Institution - 001-951 - A
    Denver, Colorado 80218, United States
  • Local Institution - 001-951 - B
    Denver, Colorado 80218, United States
  • Local Institution - 001-846
    Grand Junction, Colorado 81501, United States
  • Local Institution - 001-951
    Lafayette, Colorado 80026, United States
  • Local Institution - 001-872-A
    Lakewood, Colorado 80228, United States
  • Local Institution - 001-872-D
    Littleton, Colorado 80218, United States
  • Local Institution - 001-872-K
    Lone Tree, Colorado 80124, United States
  • Local Institution - 001-872-C
    Longmont, Colorado 80501, United States
  • Local Institution - 001-872-J
    Parker, Colorado 80138, United States
  • Local Institution - 001-872-F
    Pueblo, Colorado 81008, United States
  • Local Institution - 001-872-G
    Pueblo, Colorado 81008, United States
  • Local Institution - 001-872-I
    Thornton, Colorado 80260, United States
  • Local Institution - 001-816
    New Haven, Connecticut 06510, United States
  • Local Institution - 001-871
    Newark, Delaware 19713-2055, United States
  • Local Institution - 001-929i
    Altamonte Springs, Florida 32701, United States
  • Local Institution - 001-839
    Boca Raton, Florida 33432, United States
  • Local Institution - 001-922A
    Bonita Springs, Florida 34135, United States
  • Local Institution - 001-922D
    Bradenton, Florida 34211, United States
  • Local Institution - 001-929c
    Brandon, Florida 33511, United States
  • Local Institution - 001-922E
    Cape Coral, Florida 33909, United States
  • Local Institution - 001-929g
    Clearwater, Florida 33761, United States
  • Local Institution - 001-926b
    Daytona Beach, Florida 32117, United States
  • Local Institution - 001-922
    Fort Myers, Florida 33901, United States
  • Local Institution - 001-922B
    Fort Myers, Florida 33905, United States
  • Local Institution - 001-922C
    Fort Myers, Florida 33908, United States
  • Local Institution - 001-929b
    Gainesville, Florida 32605, United States
  • Local Institution - 001-829
    Jacksonville, Florida 32224, United States
  • Local Institution - 001-929m
    Lady Lake, Florida 32159, United States
  • Local Institution - 001-929e
    Largo, Florida 33770, United States
  • Local Institution - 001-929n
    Lecanto, Florida 34461, United States
  • Local Institution - 001-870
    Miami, Florida 33176, United States
  • Local Institution - 001-825
    Miami Beach, Florida 33140, United States
  • Local Institution - 001-922F
    Naples, Florida 34102, United States
  • Local Institution - 001-922G
    Naples, Florida 34102, United States
  • Local Institution - 001-538
    Ocala, Florida 34474, United States
  • Local Institution - 001-929p
    Ocala, Florida 34474, United States
  • Local Institution - 001-914
    Orange City, Florida 32763, United States
  • Local Institution - 001-929j
    Orange City, Florida 32763, United States
  • Local Institution - 001-929l
    Orlando, Florida 32806, United States
  • Local Institution - 001-877
    Pensacola, Florida 32503, United States
  • Local Institution - 001-922H
    Port Charlotte, Florida 33980, United States
  • Local Institution - 001-922I
    Sarasota, Florida 34232, United States
  • Local Institution - 001-922J
    Sarasota, Florida 34236, United States
  • Local Institution - 001-929h
    Spring Hill, Florida 34608, United States
  • Local Institution - 001-929a
    St. Petersburg, Florida 33705, United States
  • Local Institution - 001-929
    St. Petersburg, Florida 33705, United States
  • Local Institution - 001-926d
    Stuart, Florida 34994, United States
  • Local Institution - 001-929d
    Tampa, Florida 33607, United States
  • Local Institution - 001-929k
    Tavares, Florida 32778, United States
  • Local Institution - 001-929f
    Trinity, Florida 34655, United States
  • Local Institution - 001-922K
    Venice, Florida 34285, United States
  • Local Institution - 001-922L
    Venice, Florida 34292, United States
  • Local Institution - 001-926c
    Vero Beach, Florida 32960, United States
  • Local Institution - 001-926a
    Wellington, Florida 33414, United States
  • Local Institution - 001-926
    West Palm Beach, Florida 33401, United States
  • Local Institution - 001-929o
    Winter Park, Florida 32789, United States
  • Local Institution - 001-967
    Athens, Georgia 30607, United States
  • Local Institution - 001-835-C
    Austell, Georgia 30106, United States
  • Local Institution - 001-835-E
    Austell, Georgia 30106, United States
  • Local Institution - 001-835-D
    Carrollton, Georgia 30117, United States
  • Local Institution - 001-835-F
    Carrollton, Georgia 30117, United States
  • Local Institution - 001-835-A
    Cartersville, Georgia 30121, United States

Showing the first 100 of 222 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Negrao MV, Spira AI, Heist RS, Janne PA, Pacheco JM, Weiss J, Gadgeel SM, Velastegui K, Yang W, Der-Torossian H, Christensen JG, Sabari JK. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol. 2023 Oct 1;41(28):4472-4477. doi: 10.1200/JCO.23.00046. Epub 2023 Jun 16. PubMed 37327468 ↗
  • Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26. PubMed 37099736 ↗
  • Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21. PubMed 36546659 ↗
  • Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3. PubMed 35658005 ↗
  • Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy SR, Gainor JF, Rajan AP, Nieblas-Bedolla E, Burns AC, Hallin J, Olson P, Christensen JG, Kurz SC, Brastianos PK, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. doi: 10.1158/1078-0432.CCR-22-0383. PubMed 35404402 ↗
  • Ou SI, Janne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). J Clin Oncol. 2022 Aug 10;40(23):2530-2538. doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15. PubMed 35167329 ↗
  • Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Janne PA, Aguirre AJ. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. PubMed 34161704 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jun 2026, 89 months.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's 89 months is above that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2018
First posted
Dec 24, 2018
StartActual
Jan 15, 2019
Primary completionActual
Jun 23, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03785249
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Jan 15, 2019
Primary completion
Jun 23, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adagrasib

Start the discussion